Growth Hormone Therapy
Recombinant human growth hormone replacement to restore youthful GH/IGF-1 levels and support body composition, recovery, and vitality.
Evidence Summary
Growth hormone therapy has a well-established role in adults with documented GH deficiency (from pituitary disease, surgery, or radiation), where it improves body composition, bone density, lipids, and quality of life. Its use purely for anti-aging in otherwise healthy older adults is far more controversial and is not FDA-approved for that purpose. The most rigorous synthesis — a 2007 Annals of Internal Medicine systematic review of randomized trials in healthy older adults (18 study populations, 220 GH-treated participants, mean age 69) — found only modest body-composition changes: lean body mass rose about 2.1 kg and fat mass fell about 2.1 kg, with essentially no change in body weight and no improvement in most functional outcomes, while soft-tissue edema, joint pain, carpal tunnel syndrome, gynecomastia, and glucose intolerance were significantly more common; the authors concluded GH cannot be recommended as an anti-aging therapy. Complicating the picture, reduced GH/IGF-1 signaling — not more of it — is what most reliably extends lifespan in animal models: GH- or GH-receptor-deficient mice live roughly twice as long as normal, and 2024–2025 reviews link GH excess to hypothalamic and systemic inflammation and to GH/IGF-1 pathways implicated in cancer, whereas lower IGF-1 tone is associated with longevity. Early human work is intriguing but preliminary — a small uncontrolled 2019 trial (TRIIM, n=9) using GH combined with DHEA and metformin reported an approximately 2.5-year reduction in epigenetic age over one year, but the effect cannot be attributed to GH alone. Net: strong evidence for correcting true deficiency; weak and mixed evidence, with real risks and a biologically plausible longevity trade-off, for anti-aging use in people with normal GH levels.
Evidence Scale
Mechanism of Action
Growth hormone (GH), released by the pituitary, stimulates hepatic and local production of insulin-like growth factor-1 (IGF-1), driving protein synthesis, lipolysis, and tissue repair and shaping body composition. In documented GH deficiency, replacement restores these anabolic signals. The same axis sits at the center of a longevity paradox: sustained GH/IGF-1 signaling promotes growth and cell proliferation, while genetically or nutritionally lowered GH/IGF-1 tone extends lifespan and delays age-related disease in multiple animal models. GH excess is linked to hypothalamic and systemic low-grade inflammation and to proliferative (including pro-cancer) signaling, which is why the goal in most healthy adults is an optimal — not maximal — IGF-1 level.
Who Is This For?
GH deficiency, adult-onset decline, quality of life impairment. IGF-1 and metabolic baseline required.
Protocol & Dosing
Dose
0.1-0.3mg daily (anti-aging) to 0.4-0.8mg (replacement). Target IGF-1 200-280 ng/mL.
Frequency
Daily
Duration
Ongoing with monitoring
Protocol Summary
Daily subcutaneous injection, typically evening. Start low and titrate to IGF-1 target.
Latest Evidence
GH and aging: modest benefits, real risks, and a longevity paradox
Growth hormone (GH) has a clear, established role in adults with diagnosed GH deficiency. Its use purely for anti-aging in healthy older adults is far more contested and is not FDA-approved. The most rigorous synthesis — a systematic review of randomized trials in healthy older adults (18 study populations, 220 GH-treated participants, mean age 69) — found only modest body-composition changes: lean body mass rose about 2.1 kg and fat mass fell about 2.1 kg, with no meaningful change in body weight or most functional outcomes, while soft-tissue edema, joint pain, carpal tunnel syndrome, gynecomastia, and glucose intolerance were significantly more common. The authors concluded GH “cannot be recommended as an anti-aging therapy.”
Adding to the caution, it is lower GH/IGF-1 signaling — not more — that most reliably extends lifespan in animals: GH- or GH-receptor-deficient mice live roughly twice as long as normal, and 2024–2025 reviews tie GH excess to hypothalamic and systemic inflammation and to growth-promoting pathways implicated in cancer. Early human data are intriguing but preliminary — a small uncontrolled 2019 trial (TRIIM, n=9) using GH together with DHEA and metformin reported an ~2.5-year reduction in epigenetic age over a year, but the effect cannot be attributed to GH alone.
Educational information, not medical advice. GH is a prescription hormone; distributing it for anti-aging is illegal in the US. It is appropriate only for medically diagnosed deficiency under specialist supervision, with screening for malignancy, diabetes, and diabetic retinopathy. The goal in most adults is an optimal — not maximal — IGF-1 level.
Meta-analysis · 18 RCT populations · 220 GH-treated adults
Body-composition change on GH vs. no GH
Source: Liu et al., Annals of Internal Medicine, 2007 — systematic review and meta-analysis of randomized trials of growth hormone in healthy older adults (mean age 69). Changes shown are GH vs. no GH. Benefits were modest and accompanied by significantly higher rates of edema, joint pain, carpal tunnel syndrome, gynecomastia, and glucose intolerance; the authors concluded GH cannot be recommended as an anti-aging therapy.
Related on Peak Human
Hormone Optimization
Physician-supervised hormone & metabolic optimization.
Advanced Testing
Baseline IGF-1, glucose, and metabolic panels.
Hormone Goals
Peak Human's hormone-focused pathway.
Peptide Therapy
GH secretagogues (CJC-1295, Ipamorelin) as an alternative.
DHEA
Studied alongside GH in the TRIIM thymus protocol.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Liu et al., GH in the healthy elderly — Ann. Intern. Med. (2007) · Velloso & Donato, GH, hypothalamic inflammation & aging — J. Obes. Metab. Syndr. (2024) · Johnston & Brown-Borg, somatotropic axis & muscle aging — Ageing Res. Rev. (2025) · Fanti & Longo, GH/IGF-1 signaling & cancer — Endocr. Relat. Cancer (2024) · Fahy et al., epigenetic age reversal (TRIIM) — Aging Cell (2019)
Interactions & Precautions
Contraindications
- Active malignancy
- Diabetic retinopathy
- Uncontrolled diabetes
- Acromegaly
Potential Risks
- •Cancer promotion (theoretical)
- •Diabetes risk
- •Cost
- •Joint issues
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Reserve GH replacement for adults with biochemically confirmed deficiency; it is not FDA-approved for anti-aging and is illegal to distribute for that purpose in the US. Confirm the diagnosis with dynamic testing and baseline IGF-1, glucose/HbA1c, and screen for malignancy and diabetic retinopathy before starting. Titrate to an age-appropriate IGF-1 target rather than a maximal level, and monitor IGF-1, fasting glucose/HbA1c, and edema/joint symptoms. GH secretagogues (e.g., CJC-1295, Ipamorelin) are sometimes used as an alternative but have limited long-term outcome data. Given animal evidence that lower GH/IGF-1 tone favors longevity, weigh body-composition benefits against a plausible long-term trade-off.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation